Exelixis, Inc. $EXEL Shares Bought by Impact Partnership Wealth LLC

Impact Partnership Wealth LLC grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 14.2% during the second quarter, Holdings Channel reports. The firm owned 8,345 shares of the biotechnology company’s stock after acquiring an additional 1,038 shares during the quarter. Impact Partnership Wealth LLC’s holdings in Exelixis were worth $368,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Fuller & Thaler Asset Management Inc. increased its holdings in shares of Exelixis by 2.2% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company’s stock worth $287,794,000 after acquiring an additional 164,134 shares during the period. AQR Capital Management LLC increased its holdings in shares of Exelixis by 73.8% in the 1st quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after acquiring an additional 2,926,884 shares during the period. Invesco Ltd. increased its holdings in shares of Exelixis by 40.2% in the 1st quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after acquiring an additional 1,596,948 shares during the period. Nuveen LLC acquired a new stake in shares of Exelixis in the 1st quarter worth about $123,310,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Exelixis by 2.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,321,407 shares of the biotechnology company’s stock worth $122,626,000 after acquiring an additional 69,054 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Trading Down 1.2%

Exelixis stock opened at $38.94 on Friday. The stock has a market cap of $10.48 billion, a price-to-earnings ratio of 18.72, a PEG ratio of 0.79 and a beta of 0.38. The company’s 50-day moving average price is $38.81 and its two-hundred day moving average price is $40.21. Exelixis, Inc. has a 52 week low of $31.90 and a 52 week high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company had revenue of $568.26 million during the quarter, compared to analyst estimates of $574.36 million. During the same quarter last year, the firm posted $0.84 EPS. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. Research analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Wall Street Zen raised shares of Exelixis from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a report on Tuesday, July 29th. Morgan Stanley dropped their price objective on shares of Exelixis from $50.00 to $44.00 and set an “overweight” rating on the stock in a report on Tuesday, October 21st. Truist Financial lowered their target price on shares of Exelixis from $56.00 to $49.00 and set a “buy” rating on the stock in a research note on Tuesday, July 29th. Finally, Guggenheim reissued a “buy” rating and set a $45.00 target price on shares of Exelixis in a research note on Tuesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, Exelixis currently has a consensus rating of “Moderate Buy” and an average price target of $44.53.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.